Immix Biopharma, Inc. 8-K

What Happened
Immix Biopharma, Inc. (IMMX) announced on March 25, 2026 that it entered into Amendment No. 1 to its At-The-Market Offering Agreement with Citizens JMP Securities, LLC. The amendment covers an "at the market" offering under the company’s effective Form S-3 registration (File No. 333-292665) and permits the company to offer and sell up to $100,000,000 aggregate of its common stock from time to time.

Key Details

• Date of amendment: March 25, 2026; original sales agreement dated June 3, 2025.
• Maximum aggregate offering size: $100,000,000 of common stock.
• Sales agent: Citizens JMP Securities, LLC; commission: 3.0% of gross sales proceeds.
• Company will reimburse specified agent expenses up to $50,000 and provided customary indemnification/contribution rights.
• Sales will be made under the company’s Form S-3 registration statement (declared effective Jan 22, 2026) and are subject to limitations (registered shares available, authorized but unissued shares, and Form S-3 sale limits).

Why It Matters
This amendment gives Immix a ready mechanism to raise capital by selling shares into the market as needed. If the company sells shares under this program, it would increase the number of shares outstanding and dilute existing shareholders; investors should watch for any announced sales, timing, and pricing. The specific economics of any issuance (amount sold, price received after the 3% commission, and timing) will determine the financial impact. The filing also includes a legal opinion from Blank Rome LLP regarding the validity of the shares.